Found 29 articles for: "safety"
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata
March 2026 | Volume 25 | Issue 3 | Original Article | 204 | Copyright © March 2026
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss on the scalp and body, leading to a reduced quality of life and psychosocial burden for patients. The only US ...
Read MoreBrodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
March 2026 | Volume 25 | Issue 3 | Original Article | 211 | Copyright © March 2026
Background: Plaque psoriasis is a chronic immune-mediated disease driven by proinflammatory cytokines. Brodalumab--a recombinant, human monoclonal antibody that functions as an i...
Read MoreBaricitinib-Related Adverse Events in Alopecia Areata and Rheumatoid Arthritis: A Comparative Study
March 2026 | Volume 25 | Issue 3 | Features | 286 | Copyright © March 2026
Characterizing Safety Outcomes of a Dermal Filler: Injection Site and Timing Insights from the Maude Database
January 2026 | Volume 25 | Issue 1 | Original Article | 81 | Copyright © January 2026
Background: Juvéderm Volbella distinguishes itself for being the only hyaluronic acid filler with dual FDA approval for perioral and infraorbital regions. Its Vycross tech...
Read MoreCutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024
January 2026 | Volume 25 | Issue 1 | Original Article | 11 | Copyright © January 2026
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for conditions beyond type 2 diabetes, including psoriasis and hidradenitis suppurat...
Read MoreSunless Tanners in Dermatology: A Review of Ingredients, Efficacy, and Safety Profiles
January 2026 | Volume 25 | Issue 1 | Original Article | 30 | Copyright © January 2026
Background: Sunless tanners offer a safer alternative to ultraviolet (UV)-based tanning but may cause adverse skin reactions, including irritant and allergic contact dermatitis. ...
Read MoreFDA Boxed Warnings: Should Package Inserts Include Levels of Evidence?
December 2025 | Volume 24 | Issue 12 | Features | e67 | Copyright © December 2025
Many medications commonly used in dermatology come with package inserts that contain boxed warnings that are frequently not evidence-based. Boxed warnings are the most serious warnings that the U...
Read MoreImpact of Low-Dose Oral Minocycline (DFD-29) on Skin, Gastrointestinal, and Vaginal Microflora in Healthy Adults
December 2025 | Volume 24 | Issue 12 | Original Article | 1222 | Copyright © December 2025
Background: DFD-29 (minocycline hydrochloride extended-release capsules, 40 mg) has shown significant therapeutic benefit vs placebo and doxycycline in treating moderate-to-sever...
Read MoreMethotrexate Test Dose Use and Frequency of Laboratory Abnormalities in Patients Initiating Treatment
November 2025 | Volume 24 | Issue 11 | Original Article | 1132 | Copyright © November 2025
Background: Recent guidelines within the dermatology literature have indicated that a methotrexate test dose may not be needed for patients at lower risk of toxicity. However, fe...
Read MorePerceptions and Recommendations for Sunscreen: A Cross-Sectional Survey of United States Dermatology Healthcare Providers
November 2025 | Volume 24 | Issue 11 | Original Article | 1113 | Copyright © November 2025
Read MoreCaffeine Supplementation and Hair: A Systematic Review
November 2025 | Volume 24 | Issue 11 | Original Article | 1070 | Copyright © November 2025
Background: While caffeine has been proposed to stimulate hair growth, its safety and efficacy remain unclear. This systematic review evaluates the effects of caffeine interventi...
Read MoreConnecting the Plaques: Exploring the Link Between Dupilumab and Cutaneous T-cell Lymphoma
November 2025 | Volume 24 | Issue 11 | Features | 1148 | Copyright © November 2025
The Dermatologic Hazards of Nail Product Usage
October 2025 | Volume 24 | Issue 10 | Features | 1051 | Copyright © October 2025
The major dermatologic adverse effect of nail polish that has been reported is an allergic contact dermatitis. This can within the ungual and periungual region, but it can also be diffuse and spr...
Read MoreRetrospective Review of Dermal Safety Studies of Organic Sunscreens
September 2025 | Volume 24 | Issue 9 | Original Article | 897 | Copyright © September 2025
Read MoreSafety and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Truncal Acne
August 2025 | Volume 24 | Issue 8 | Original Article | 803 | Copyright © August 2025
Background: Truncal acne is underdiagnosed and undertreated, and it can lead to scarring and postinflammatory hyperpigmentation. However, applying topical treatments to larger sk...
Read MoreA Single-Center Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis
June 2025 | Volume 24 | Issue 6 | Original Article | 617 | Copyright © June 2025
Background: Periorificial dermatitis (POD) is a facial skin rash often found in the oral commissures and nasolabial folds, and around the eyes. Treatment options include topical ...
Read MoreThe Impact on Acne Treatment Regimens if Benzoyl Peroxide-Containing Products are Removed From the Market
June 2025 | Volume 24 | Issue 6 | Features | 586 | Copyright © June 2025
Benzyl peroxide (BPO) has been an important component of many acne treatment regimens. However, an independent testing laboratory, Valisure, filed a Citizen’s Petition with the US Food and ...
Read MoreWeight Change and Dose Adjustment in Isotretinoin Therapy: A Retrospective Study
June 2025 | Volume 24 | Issue 6 | Features | 639 | Copyright © June 2025
Isotretinoin is used to treat severe nodulocystic acne. Cumulative doses of 120 to 150 mg/kg have been shown to limit adverse events while maximizing efficacy. Also proven safe, doses of 220 mg/k...
Read MoreIs Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
May 2025 | Volume 24 | Issue 5 | Original Article | 530 | Copyright © May 2025
Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition associated with risk of cardiovascular disease (CVD), potentially mediated by persistent systemic infl...
Read MoreA Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel
February 2025 | Volume 24 | Issue 2 | Original Article | 147 | Copyright © February 2025
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
